- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Case Reports in Dermatological Medicine
Volume 2012 (2012), Article ID 207126, 6 pages
Paraneoplastic Pemphigus: A Paraneoplastic Autoimmune Multiorgan Syndrome or Autoimmune Multiorganopathy?
1Department of Dermatology, Venereology & Leprosy, Dr. R. P. Govt. Medical College, Kangra, Tanda, Himachal Pradesh 176001, India
2Department of Pathology, Dr. R. P. Govt. Medical College, Kangra, Tanda, Himachal Pradesh 176001, India
3Department of Radiotherapy & Oncology, Dr. R. P. Govt. Medical College, Kangra, Tanda, Himachal Pradesh 176001, India
Received 30 October 2012; Accepted 3 December 2012
Academic Editors: J. Y. Lee, N. Oiso, and R. Strohal
Copyright © 2012 Vikram K. Mahajan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Paraneoplastic pemphigus (PNP), a clinically and immunopathologically distinct mucocutaneous blistering dermatosis, is a severe form of autoimmune multiorgan syndrome generally associated with poor therapeutic outcome and high mortality. This IgG-mediated disease is initiated by an obvious or occult lymphoproliferative disorder in most cases. Clinically severe mucositis, and polymorphic blistering skin eruptions, and histologically acantholysis, keratinocyte necrosis and interface dermatitis are its hallmark features. A 58-year-old female presented with recurrent, severe, recalcitrant stomatitis and widespread erosions/blistering lesions of one-year duration. Treatment with repeated courses of systemic corticosteroids at a peripheral center would provide temporary relief. She also had fever, productive cough, odynophagia and poor oral intake, herpes zoster ophthalmicus, pain in the abdomen, and watery diarrhea. An array of investigations revealed chronic lymphocytic leukemia (CLL), mediastinal and para-aortic lymphadenopathy, bronchiolitis obliterans, and vertebral osteoporosis/fractures. With the diagnosis of CLL-associated PNP she was managed with dexamethasone-cyclophosphamide pulse (DCP) therapy for 3 cycles initially, followed by COP regimen (cyclophosphamide, vincristine, and prednisolone) for 5 cycles. Remission is being maintained with chlorambucil and prednisolone pulse therapy once in 3 weeks with complete resolution of skin lesions and adequate control of CLL.
Paraneoplastic pemphigus (PNP) is a mucocutaneous disease due to immunological effects of the tumor on resident immune system rather than by direct tumor infiltration or tissue damage caused by metastasis . Although no age group or gender is exempt, the affected individuals in most instances are between 45 and 70 years of age and are males [2, 3]. This IgG-mediated disease is initiated by an obvious or occult lymphoproliferative disorder in most cases. Clinically severe mucositis and polymorphic blistering skin eruptions and histologically acantholysis, keratinocyte necrosis, and interface dermatitis are its hallmark features. Immunoprecipitation and immunoblot testing will detect autoantibodies directed against a complex of four polypeptides (mainly plakin family proteins and desmogleins) with different molecular weights: periplakin (210 and 190 kDa), desmoplakins-I and II (250 and 210 kDa), bullous pemphigoid antigen-1 (BPAG-I, 230 kDa), and envoplakin-I (210 kDa) [3, 4]. Pulmonary involvement as bronchiolitis obliterans is frequent, mostly irreversible and often fatal [5, 6]. The varied clinical and immunological presentations have led to revisions of the original criteria (Table 1) of Anhalt et al.  for diagnosis of PNP over the years. The simplified and most referred diagnostic criteria are proposed by Camisa et al.  and include three major criteria: (1) polymorphic mucocutaneous eruptions, (2) concurrent internal neoplasia, and (3) serum antibodies with specific immunoprecipitation pattern, and three minor criteria: (1) histologic evidence of acantholysis, (2) direct immunofluorescence (DIF) showing intercellular and basement membrane staining (for IgG and Compliment), and (3) indirect immunofluorescence (IIF) staining with rat bladder epithelium for circulating autoantibodies. Presence of 3 major or 2 major and 2 minor of these criteria is considered diagnostic. Response to treatment is generally poor with significant morbidity and mortality.
The disease occurs worldwide and about 450 cases have been reported in the literature between 1990 and 2011 . It is not frequently reported in India; a PubMed and IndMed search on September 10, 2012, revealed only one report of phaeochromocytoma-associated PNP by Dave et al.  in the perspective of anesthetic management of their patient. In this paper we describe another case of PNP with an idea to share our experience of managing this case.
2. Case Report
This 58-year-old female presented with recurrent, multiple, flaccid bullae, and erosions with oozing and crusting at places and severe painful oral ulcerations of 1-year duration. Various treatments including repeated courses of systemic corticosteroids at a peripheral center would provide temporary relief but recurrences and exacerbations were causing marked discomfort and disability. The cutaneous lesions were widespread and predominantly distributed over trunk and limbs. She had severe erosions/ulceration of the vermilion lips, palate and tongue (Figure 1), and conjunctival congestion (conjunctivitis). Oral lesions had preceded the skin lesion by 2 months. She also had episodes of moderate to high fever, productive cough and breathlessness, easy fatigability, bouts of abdominal pain, and watery diarrhea. She was sick, experienced pain while swallowing, dehydrated and had multiple crusted and denuded skin and few flaccid bullae over face, abdomen, back and limbs involving about 30% body surface area. The painful erosive lesions over right forehead were suggestive of herpes zoster ophthalmicus. Tzanck smear from a skin erosion and right forehead lesion showed acantholytic cells (Figure 2) and multinucleated giant cells (for herpes zoster), respectively. The deposition of IgG and complement in the basement membrane zone and intercellularly in the epidermis were seen on direct immunofluorescence (DIF) of perilesional skin. Histologic features of suprabasal acantholysis, dyskeratotic keratinocytes, and/or basal vacuolization and interface dermatitis (dyskeratotic keratinocytes, basal vacuolization, epidermal exocytosis) and absence of eosinophilic spongiosis and inflammatory infiltrate of eosinophils and neutrophils within the superficial dermis were suggestive of PNP (cf. pemphigus vulgaris). (Figure 3). Lab workup showed low hemoglobin (7.5 gm%), leukocytosis with predominant lymphocytosis (total leucocyte count 38900/cmm, L89%, N11%), elevated erythrocyte sedimentation rate (ESR 60 mm in 1st hr, Westergren method), and normal platelet counts (2,63000/cmm). Peripheral blood film showed dimorphic anemia and chronic lymphocytic leukemia (CLL) picture (Figure 4). Serum urea and creatinine were 59 mg% and 1.4 mg%, respectively. Hepatic functions, blood glucose, serum electrolytes, and urinalysis were essentially normal. Fine needle aspiration cytology from a small axillary lymph node showed features of small cell lymphocytic lymphoma/CLL (Figure 5). Radio-imaging studies (Figures 6 and 7) showed bilateral hilar lymphadenopathy and segmental atelectasis in chest X-rays and retroperitoneal lymph node enlargement involving those from epigastrium to aortic bifurcation and external iliac group, concentric thickening of sigmoido-rectal wall and fractured/collapsed vertebrae in ultrasonography (USG) and computed tomography (CT scan) of abdomen. The pathology of thickened sigmoido-rectal wall could not be ascertained as she did not consent for the colonoscopic biopsy due to ill health.
2.1. Management and Course in the Hospital
With the diagnosis of CLL-associatedparaneoplastic pemphigus, bronchilitis obliterans, and iatrogenic (steroid induced) vertebral fractures, she was put on treatment with dexamethasone-cyclophosphamide-pulse (DCP) therapy (dexamethasone 100 mg in 500 mL of 5% dextrose given by a slow IV infusion over 2-3 hours on three consecutive days along with 500 mg of cyclophosphamide IV on the second day and repeat DCP doses at 3-week interval). Prednisone 40 mg/d and cyclophosphamide 50 mg/d PO during intervening days between two DCPs were added. She also received aciclovir 800 mg five times/d and amoxiclav 1 gm twice/d for 1 week, probiotics, nutritional supplements, and other supportive measures. For CLL, cyclophosphamide was considered adequate. During next 2 months of hospitalization most of her mucocutaneous lesions showed epithelization/healing, oral intake of food/fluids and general wellbeing improved, and she had no recurrence of diarrhea. After 3 DCPs she was put on COP regimen (single intravenous dose of cyclophosphamide 1 gm and oncovin/vincristine 1 mg, and prednisolone 20 mg, t.i.d × 7 d, PO). All her skin lesions had healed and new lesions stopped coming but she developed leucopenia (TLC 2400/cmm) after 7 COP doses. She received 8th COP dose after blood counts improved (TLC 7000/cmm) following transfusion of 2 units of whole blood and 3 doses of human granulocyte colony stimulating factor (G-CSF 300 μm/d) administrated subcutaneously. Subsequently, she is being treated with chlorambucil (5 mg/d × 5 days) and prednisolone 20 mg t.i.d. × 7 days in a month, PO. Her skin lesions are in remission, the sigmoido-rectal thickening has reduced and all involved lymph nodes are reduced in size and number as seen in repeat CT scan abdomen.
Anhalt et al.  in 1990, suggested the name paraneoplastic pemphigus for a pemphigus variant with underlying neoplasms wherein painful mucosal ulcerations and polymorphous skin lesions develop and is characterized by pathogenic autoantibodies directed against desmoplakin-I, BPAG-I, envoplakin-I, and periplakin. Its clinical presentation often mimics a drug reaction, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis and wide variety of morphologic variants have been recognized: pemphigus-like, bullous pemphigoid-like, erythema multiforme-like, graft-versus-host disease-like, lichen planus-like and pemphigu vegetans-like [5, 10, 11]. Almost 2/3 of the cases arise in the context of a known (benign or malignant) neoplasia and hematologic neoplasms constitute about 84% of PNP cases while others may follow cytotoxic drug therapy [12–14]. Chronic lymphocytic leukemia (18.4%), non-Hodgkin’s lymphoma (38.6%), Castleman’s disease (18.4%), and benign thymoma (5.5%) were among the most common neoplasms in one series of 163 cases . Nonhematologic malignancies constitute nearly 58% cases and also include carcinomas of epithelial origin (8.6%), sarcomas of mesenchymal origin (6.2%), and malignant melanoma (0.6%) . Reticulum cell sarcoma, retroperitoneal spindle cell sarcoma, and Waldenstrom’s macroglobulinemia are other common associated neoplastic disorders [12, 14]. Interestingly PNP may be an initial presentation of underlying neoplasia or present as a late consequence after complete resection of neoplasia [14, 15]. Chronic lymphocytic leukemia (a B-cell malignancy due to clonal proliferation of a CD5+ subpopulation), a common hematologic malignancy especially among elderly (above 50 years of age) in the Western world, has the most common association with PNP [3, 14]. On the other hand, PNP may be a presenting feature of occult Castleman’s disease in children [3, 10, 16]. Reportedly, pulmonary involvement (bronchilitis obliterans) is more common with Castleman’s disease-associated PNP and was noted in 26 of 28 cases by Nikolskaia et al.  and 7 of 10 cases by Wang et al. . There is enough evidence to suggest that this results from antibody-mediated (both humoral and cell-mediated autoimmunities) acantholysis in bronchial epithelium due to the presence of desmoplakin in respiratory tract . Cutaneous histology shows significant variability corresponding to the clinical presentation and age of the lesion . While in DIF combination of IgG and complement deposition along the basement membrane zone and/or in the epidermal intercellular spaces is seen, staining of rodent bladder epithelium for polyclonal IgG (subclasses) and light chains is a feature on indirect immunofluorescence (IIF) [6, 14]. However, immunoprecipitation or immunoblotting is the standard diagnostic test but both are not readily available for wide use.
Majority of these cases have been treated as pemphigus vulgaris for want of clinical suspicion. Nevertheless, they require extensive investigative workup to exclude associated neoplasia. Although our patient had severe mucocutaneous erosions/ulceration particularly of oral cavity/vermilion lip and cutaneous bullous/ulcerative lesions, and histology and DIF features suggestive of classic PNP, she remained undiagnosed for want of clinical suspicion. She was managed at a peripheral center as a case of pemphigus vulgaris with systemic corticosteroids without significant benefit despite their side effects. Bronchilitis obliterans which is far more common in Castleman’s disease-associated PNP and gastrointestinal symptoms were uncommon features in her. Together with conjunctivitis all were suggestive of multiorganopathy.
For the autoimmune phenomenon treatment with systemic corticosteroids in high doses is needed; addition of cyclosporine-A, DCP therapy, cyclophosphamide, mycophenolate mofetil, or azathioprine will curtail steroid intake and their side-effects. Intravenous immunoglobulin (IVIG), rituximab and alemtuzumab, plasmapheresis, and photopheresis are some other modalities of promising efficacy [3, 6]. The skin lesions respond better than mucosal (oral/bronchial) lesions which are highly refractory to treatment. Additionally, treatment of the underlying neoplasia is of paramount importance. For the treatment of CLL options include chemotherapy, chlorambucil, COP or CHOP regimen, and fludarabine, given alone or in combination. However, there is no recommended drug regimen that is consistently effective. We treated our patient with DCP therapy initially as it was considered effective for both autoimmune phenomenon and CLL and later with COP/CHOP regimens after the acute phase subsided. Adequate remission has been maintained with chlorambucil in combination with prednisolone. However, ultimate benefit cannot be comprehended at the moment as prolonged survival is uncommon and depends upon underlying neoplasia.
Czernik et al.  suggested that term “paraneoplastic pemphigus” does not adequately address this multiorgan syndrome of varied signs and symptoms. Moreover pulmonary involvement is not a usual feature of pemphigus. Bronchilitis obliterans is a common feature seen in 30–40% of PNP cases , while the involvement of mucous membranes of esophagus, stomach, duodenum, and colon is infrequent in contrast to their involvement in pemphigus. This combined with reports of glomerulonephritis, neurological involvement, and ocular involvement (conjunctivitis, symblepharon, and corneal scarring) in PNP are further suggestive of this being a disease of multiorgan system [19, 20]. We tend to agree with Czernik et al.  that “paraneoplastic autoimmune multiorgan syndrome (PAMS)” is more inclusive nomenclature. However, we believe that the term “paraneoplastic autoimmune multiorganopathy” both clinically and pathogenetically will be more precise, unambiguously encompasses the heterogeneous manifestations of this distinct paraneoplastic process, and is perhaps more appropriate to use. Nevertheless, our viewpoints remain open for discussion.
Conflict of Interests
The authors declare that they have no conflict of interests.
- G. J. Anhalt, “Paraneoplastic Pemphigus,” Journal of Investigative Dermatology Symposium Proceedings, vol. 9, no. 1, pp. 29–33, 2004.
- A. Kimyai-Asadi and M. H. Jih, “Paraneoplastic pemphigus,” International Journal of Dermatology, vol. 40, no. 6, pp. 367–372, 2001.
- V. N. Sehgal and G. Srivastava, “Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome,” International Journal of Dermatology, vol. 48, no. 2, pp. 162–169, 2009.
- S. E. Lee and S. C. Kim, “Paraneoplastic pemphigus,” Dermatologica Sinica, vol. 28, no. 1, pp. 1–14, 2010.
- V. T. Nguyen, A. Ndoye, K. D. Bassler et al., “Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus,” Archives of Dermatology, vol. 137, no. 2, pp. 193–206, 2001.
- A. Czernik, M. Camilleri, M. R. Pittelkow, and S. A. Grando, “Paraneoplastic autoimmune multiorgan syndrome: 20 years after,” International Journal of Dermatology, vol. 50, no. 8, pp. 905–914, 2011.
- G. J. Anhalt, S. C. Kim, J. R. Stanley et al., “Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia,” New England Journal of Medicine, vol. 323, no. 25, pp. 1729–1735, 1990.
- C. Camisa, T. N. Helm, Y. C. Liu et al., “Paraneoplastic pemphigus: a report of three cases including one long-term survivor,” Journal of the American Academy of Dermatology, vol. 27, no. 4, pp. 547–553, 1992.
- S. T. Dave, V. Chandrashekhar, S. K. Kamath, and L. V. Dewoolkar, “Anaesthetic management for paraneoplastic pemphigus,” Indian Journal of Anaesthesia, vol. 51, pp. 525–527, 2007.
- J. E. Lane, C. Woody, L. S. Davis, M. F. Guill, and R. S. Jerath, “Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: case report and review of the literature,” Pediatrics, vol. 114, no. 4, pp. e513–e516, 2004.
- A. M. Powell, S. Albert, N. Oyama, Y. Sakuma-Oyama, B. Bhogal, and M. M. Black, “Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegetans,” Journal of the European Academy of Dermatology and Venereology, vol. 18, no. 3, pp. 360–364, 2004.
- I. Kaplan, E. Hodak, L. Ackerman, D. Mimouni, G. J. Anhalt, and S. Calderon, “Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations,” Oral Oncology, vol. 40, no. 6, pp. 553–562, 2004.
- G. J. Anhalt, “Paraneoplastic pemphigus: the role of tumours and drugs,” British Journal of Dermatology, vol. 144, no. 6, pp. 1102–1104, 2001.
- W. N. K. A. van Mook, M. M. F. Fickers, P. H. M. H. Theunissen et al., “Paraneoplastic pemphigus as the initial presentation of chronic lymphocytic leukemia,” Annals of Oncology, vol. 12, no. 1, pp. 115–118, 2001.
- M. Bębenek , “Paraneoplastic pemphigus as a late consequence of the complete resection of a skin melanoma?” Nowotwory, vol. 57, no. 4, pp. 192e–194e, 2007.
- D. Mimouni, G. J. Anhalt, Z. Lazarova et al., “Paraneoplastic pemphigus in children and adolescents,” British Journal of Dermatology, vol. 147, no. 4, pp. 725–732, 2002.
- O. V. Nikolskaia, C. H. Nousari, and G. J. Anhalt, “Paraneoplastic pemphigus in association with Castleman's disease,” British Journal of Dermatology, vol. 149, no. 6, pp. 1143–1151, 2003.
- J. Wang, X. Zhu, R. Li et al., “Paraneoplastic pemphigus associated with castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China,” Archives of Dermatology, vol. 141, no. 10, pp. 1285–1293, 2005.
- S. X. Qian, J. Y. Li, M. Hong, W. Xu, and H. X. Qiu, “Nonhematological autoimmunity (glomerulosclerosis, paraneoplastic pemphigus and paraneoplastic neurological syndrome) in a patient with chronic lymphocytic leukemia: diagnosis, prognosis and management,” Leukemia Research, vol. 33, no. 3, pp. 500–505, 2009.
- C. Laforest, S. C. Huilgol, R. Casson, D. Selva, and I. Leibovitch, “Autoimmune bullous diseases: ocular manifestations and management,” Drugs, vol. 65, no. 13, pp. 1767–1779, 2005.